Gene Expression Studies Offer Insight Into Myeloma Regimen's Efficacy

An analysis of c-MYC expression in relapsed myeloma identified subgroups of patients with improved response to the combination of an immunomodulator and a proteasome inhibitor, according to data from a randomized trial presented during the 2016 ASH Annual Meeting.1
... to read the full story